|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 11263.10 Million
|
|
Market Size (2030)
|
USD 15130.62 Million
|
|
CAGR (2025-2030)
|
6.29%
|
|
Fastest Growing Segment
|
Azoles
|
|
Largest Market
|
North India
|
Market Overview
India Anti-Fungal Drugs Market was valued at USD 11263.10 Million in 2024 and is anticipated to reach USD 15130.62 Million by 2030, with a CAGR of 6.29% during 2025-2030.
Anti fungal drugs treat infections in humans, animals, and plants, and are available as oral tablets, topical creams, and intravenous injections. These medicines target fungal cell walls, membranes, or key enzymes, stopping growth while limiting harm to human cells.
They address conditions ranging from mild skin infections such as athlete’s foot and thrush to severe systemic diseases like candidiasis and aspergillosis. Rising immunocompromised populations are increasing treatment need. In 2024, India was estimated to have 1,562,099 new cancer cases, with crude incidence rates of 107.4 per 100,000 among males and 113.3 per 100,000 among females. India also continues to carry one of the world’s largest HIV burdens, with about 2.561 million people living with HIV in 2024, an estimated 64,500 new infections, and about 32,200 AIDS-related deaths. These groups face higher fungal infection risk.
Research has introduced new drug classes and combination therapies, expanding clinical options. The COVID 19 second wave exposed shortages of antifungal medicines for mucormycosis, raising awareness and accelerating supply measures. Government programs aimed at strengthening public healthcare systems and improving access to essential medicines have supported wider availability and affordability, sustaining growth across the forecast period.
Key Report Takeaway
- Echinocandins held the largest share in 2024, driven by strong efficacy against invasive Candida and Aspergillus infections, broad-spectrum activity, and favorable safety profile.
- Azoles are projected to dominate during the forecast period, supported by versatility in treating superficial and systemic mycoses, rising resistance, and continuous formulation advancements.
- Aspergillosis accounts for the largest indication share, with high prevalence among immunocompromised patients and frequent use of targeted therapies like voriconazole and isavuconazole.
- Leading companies include Pfizer India Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Viatris Inc., Lupin Ltd., Zydus Cadila Ltd., Novartis India Ltd., and Abbott India Ltd..
Key Market Drivers
Advancements in Anti-Fungal Drugs
Advancements in anti-fungal drugs are strengthening the India anti-fungal drugs market by expanding therapeutic choice, improving route flexibility, and supporting more targeted management of invasive as well as resistant fungal infections across hospital settings. Indian treatment practice has already shifted toward newer systemic options with better clinical utility, as a multicenter Indian prescribing study covering 323 patients found posaconazole accounted for 38.6 of systemic antifungal use and anidulafungin 32.8, showing how clinicians are favoring agents with strong efficacy and safety profiles in serious infections.
This momentum is reinforced by innovations such as oral step-down therapies, liposomal and intravenous formulations, broader use of molecular diagnostics, and improved pharmacokinetic understanding that helps physicians optimize dosing in high-risk patients. Newer agents such as ibrexafungerp are also widening the pipeline by offering activity against resistant Candida species, while the CARES trial listed multiple Indian sites including Chandigarh, Bengaluru, Kochi, New Delhi, and Lucknow, underscoring India’s growing role in antifungal innovation and evidence generation. Together, these developments are improving treatment precision, stewardship focus, and long-term clinical confidence in anti-fungal therapy across India.
Growing Research and Development
R&D in India is advancing antifungal drugs with stronger efficacy, improved safety, and fewer side effects, driven by rising resistance and difficult-to-treat infections such as recalcitrant dermatophytosis. For instance, Biocon reported that Biocon Limited received US FDA approval on June 3, 2024 for Micafungin 50 mg and 100 mg vials, a complex injectable antifungal used to treat fungal or yeast infections, expanding India-linked manufacturing capability in systemic antifungals. This resistance pressure is also pushing development priorities toward broader-spectrum molecules and rational combination approaches, alongside more evidence-based treatment optimization anchored in national surveillance capacity.
Formulation science is increasingly focused on higher bioavailability, easier administration, and better adherence so that effective antifungals perform reliably in real-world use. The same national push toward data-driven decision-making is visible in government-supported infrastructure for fungal diagnostics and antifungal susceptibility mapping. For instance, a Government of India update states ICMR established the Mycology Network MycoNet in 2020 and developed eight Advanced Mycology Diagnostic and Research Centers across zones in India, connected with state governments and medical colleges for referrals and training.
Clinical trials remain central to validation and regulatory approval as next-generation agents move from promise to practice. For instance, the CARES study NCT03363841 on ClinicalTrials.gov is a multicenter, open-label, single-arm study evaluating the efficacy and safety of oral ibrexafungerp SCY-078 in adults with documented Candida auris infection, with treatment up to 90 days. At the health-system level, the same Government of India update notes that MycoNet developed a mycology clinical registry in 2023 to document invasive fungal infections and rare fungal diseases and to support antifungal susceptibility data generation for resistance monitoring in hospitals and ICUs.
During the mucormycosis surge, ensuring access to essential antifungals became a parallel priority alongside R&D and surveillance. For instance, a Ministry of Health and Family Welfare release states that, following proactive efforts, five additional manufacturers were licensed to produce Amphotericin-B in India, Natco, Alembic, Gufic, Emcure, and Lyka, and that these companies would start producing 111,000 vials per month from July 2021 with efforts to prepone some supply into June. The same release also states that 315,000 vials were planned for import in June 2021 and that total countrywide availability would be enhanced to 570,114 vials in June 2021 when combined with domestic supply, illustrating how regulatory action and supply-chain mobilization directly supported continuity of care during an emergency.
Download Free Sample Report
Key Market Challenges
High treatment cost
High treatment cost remains a significant restraint on the India anti-fungal drugs market because many advanced therapies for invasive fungal infections require prolonged treatment, hospital supervision, and repeated dosing, which together raise the total cost of care for patients and families. This affordability gap is especially serious in a market where severe infections often demand urgent initiation of therapy, leaving limited room for patients to delay, compare options, or complete treatment comfortably without financial stress.
A published Indian postmarketing study on indigenously developed liposomal amphotericin B reported that acquisition cost ranged from about Rs 4,500 to Rs 8,000 per day and roughly Rs 0.9 lakh to Rs 2.1 lakh per treatment course, highlighting how even cost-advantaged formulations can impose a heavy economic burden. Such expenses can weaken adherence, increase the likelihood of delayed treatment, and deepen access disparities for lower-income patients who may already face gaps in insurance protection or specialist care availability. As a result, pricing pressure continues to limit broader and more timely uptake of anti-fungal therapies across India despite clear clinical need.
Antifungal Resistance
Antifungal resistance is becoming a serious restraint on the India anti-fungal drugs market because it weakens the effectiveness of standard therapies, narrows physician choice, and makes fungal infections harder to control in both hospitals and community practice. As resistance expands across Candida and dermatophyte infections, physicians are often forced to use longer treatment courses, closer monitoring, and costlier second-line options, which raises the clinical and economic burden on patients as well as healthcare providers.
A systematic review of Indian Candida data showed resistance was highest in non-albicans species, reaching 47.16 in Candida haemulonii, 28.99 in Candida krusei, and 20.69 in Candida glabrata, while 10.34 of Candida albicans isolates were also reported as drug resistant, underscoring how deeply resistance is complicating routine antifungal selection. This trend increases the risk of treatment failure, persistent infection, and transmission within healthcare settings, especially among immunocompromised and critically ill patients who depend on rapid and reliable antifungal response. As a result, resistance is not only a microbiological issue but a major market barrier that pressures stewardship, diagnostics, and product development across India.
Key Market Trends
Increased Immunocompromised Patient Population
The growing immunocompromised patient population is a major demand driver for the India anti-fungal drugs market because patients with HIV, cancer, transplants, diabetes, autoimmune disorders, and intensive immunosuppressive therapy face a markedly higher risk of severe and recurrent fungal infections. This creates sustained need for both prophylactic and therapeutic antifungal use across hospitals, oncology settings, transplant programs, and long-duration care pathways where early intervention is critical to avoid complications.
The burden is already substantial, with a major India-focused review estimating 57,250,826 people are affected by serious fungal diseases and reporting annual incidence of 250,900 invasive aspergillosis cases, 188,000 candidemia cases, and 266,600 esophageal candidiasis cases in HIV, clearly showing the scale of vulnerable patients requiring antifungal treatment. Demand is further reinforced by the need for intravenous therapy, longer treatment durations, and close clinical monitoring in patients with complex comorbidities, where delayed or inadequate treatment can quickly worsen outcomes. As India’s high-risk patient base expands, anti-fungal drugs will remain essential to infection prevention, acute management, and long-term supportive care.
India Anti-fungal Market Expansion
India anti-fungal market expansion is being driven by a broader product mix, stronger hospital prescribing patterns, and rising availability of advanced systemic as well as localized therapies that allow physicians to match treatment more closely to infection severity and patient risk. The market is no longer limited to conventional oral drugs, as injectable echinocandins, liposomal amphotericin B, topical formulations, and combination strategies are gaining wider traction across tertiary care, critical care, and outpatient fungal management.
A clear indicator of this expansion comes from a multicenter Indian retrospective study spanning 127 centers and 323 patients, where posaconazole accounted for 38.6 of systemic antifungal prescriptions and anidulafungin 32.8, showing that clinicians are increasingly adopting a diversified treatment basket rather than relying on a narrow set of older molecules. This widening therapeutic base is also being supported by higher preventive use in vulnerable patients, improved awareness of invasive fungal disease, and continued participation of Indian manufacturers in complex antifungal segments such as liposomal amphotericin B and caspofungin. Together, these trends are deepening product penetration and broadening the clinical reach of anti-fungal therapies across India.
Segmental Insights
Drug Class Insights
In 2024, the India
Anti-Fungal Drugs Market largest share was held by Echinocandins drug class
segment. Echinocandins are a class
of antifungal drugs known for their effectiveness against invasive fungal
infections, particularly those caused by Candida and Aspergillus species. These
infections are common and can be life-threatening, which drives the demand for
antifungal drugs from the Echinocandins class.
Echinocandins have
broad-spectrum antifungal activity, making them effective against a range of
fungal pathogens. This versatility is a key factor in their prominence in the
market. Echinocandins are generally well-tolerated by patients, and they have a
favourable safety profile compared to some other antifungal drug classes. This
makes them a preferred choice for healthcare providers when treating serious
fungal infections.
In India Anti-Fungal Drugs market, the Azoles segment is anticipated to be dominating in the forecast period. Their broad-spectrum activity renders
them effective against a wide range of fungal species, including both
superficial and systemic infections. This versatility makes them indispensable
in the treatment of conditions ranging from superficial skin infections to
life-threatening systemic mycoses. Additionally, their relatively favorable
safety profiles and ease of administration contribute to their widespread
adoption in clinical practice.
The rise in the incidence of fungal
infections in India, driven by factors such as increasing immunocompromised
populations, widespread antifungal resistance, and a surge in invasive
procedures, underscores the need for potent antifungal agents like Azoles. The
pharmaceutical industry's response to this demand has been significant, with
continuous research and development efforts aimed at refining existing Azole
formulations and developing novel agents with enhanced efficacy and safety
profiles.
Indication Insights
In 2024, the largest share of the India Anti-Fungal Drugs Market was held by the Aspergillosis segment and is predicted to continue expanding over the coming years. Aspergillosis is a fungal infection caused by
the Aspergillus species, and it is known to be one of the more common and
clinically significant fungal infections in India. The prevalence of
Aspergillosis is relatively high, particularly in patients with compromised
immune systems, such as those with HIV/AIDS, organ transplants, or underlying
respiratory conditions.
This high prevalence drives the demand for antifungal
drugs to treat Aspergillosis. Aspergillosis can manifest in various forms,
including invasive aspergillosis, allergic bronchopulmonary aspergillosis
(ABPA), and chronic pulmonary aspergillosis (CPA). Invasive aspergillosis is a
severe and often life-threatening condition that requires aggressive antifungal
treatment. As a result, the demand for antifungal drugs is higher for this
condition. Aspergillosis requires specialized and targeted antifungal
treatment, often with drugs such as voriconazole or isavuconazole. The
complexity of treating Aspergillosis means that patients often seek care at
specialized healthcare facilities, including hospitals and medical centres,
contributing to the prominence of this segment.
Many Aspergillosis cases occur
in immunocompromised individuals, such as those undergoing chemotherapy or
organ transplantation. These patients are at higher risk of fungal infections,
including Aspergillosis, and often require hospitalization and intensive
treatment. Improved diagnostic methods have enhanced the detection of
Aspergillosis, leading to more accurate and timely diagnoses. This, in turn,
has driven the demand for antifungal drugs for Aspergillosis treatment.
Download Free Sample Report
Regional Insights
The North India region dominated the India
Anti-Fungal Drugs Market in 2024. North
India boasts highly advanced healthcare infrastructure and facilities. This
includes state-of-the-art hospitals, specialised orthopaedic and sports medicine
clinics, and a well-developed network of healthcare providers. This
infrastructure facilitates the adoption of
Anti-Fungal drug markets for various medical procedures. North India is
a leader in medical technology and research. The region is home to many
innovative medical device companies and biotechnology firms that have developed
advanced Anti-Fungal Drugs Market
products and techniques. These technological advancements have contributed to
the market's growth and dominance.
Recent Developments
- In December 2025, the CDSCO SEC (Antimicrobial & Antiviral) recommended that Gufic Biosciences conduct an active post‑marketing surveillance (PMS) study to evaluate the safety and effectiveness of Isavuconazole (as isavuconazonium sulfate) 200 mg infusion in Indian patients with invasive aspergillosis and invasive mucormycosis.
- In December 2025, the SEC note records the PMS protocol details as CRS/25/008 (Version 1.0 dated 20 November 2025) and describes it as a multicenter, open‑label, non‑comparative, interventional, prospective, active post‑surveillance study.
- In November 2025, India became the first country to approve STIMULAN Rapid Cure with antifungals, a notable product-development milestone aimed at addressing surgical site infections and antimicrobial resistance. In November 2025, the significance of the development lay in India’s first-mover role in approving an antifungal-enabled treatment platform, which positions the country as an early adopter of advanced infection-management solutions rather than only a large-volume generic market.
- In September 2025, India-led scientific approach to fight fungal infections, led by Prof. Karthik Raman of IIT Madras and Prof. Susan Thomas of ICMR-NIRRCH. In September 2025, the report said the researchers had already validated preliminary findings in animal models and were preparing to work with clinical partners and industry to translate the discovery into antifungal treatments, making it a credible breakthrough innovation linked to India’s anti-fungal drug pipeline.
Key
Market Players
- Pfizer India Ltd.
- Cipla Ltd.
- Glenmark Pharmaceuticals
Ltd.
- Sun Pharmaceuticals
Industries Ltd.
- Dr. Reddy's Laboratories
Ltd.
- Viatris Inc. (Mylan NV)
- Lupin Ltd.
- Zydus Cadila Ltd.
- Novartis India Ltd.
- Abbott India Ltd.
|
By
Drug Class
|
By
Indication
|
By
Infection Type
|
By
Route of Administration
|
By
End-User
|
By
Distribution Channel
|
By
Region
|
- Azoles
- Echinocandins
- Polyenes
- Allylamines
- Others
|
- Candidiasis
- Aspergillosis
- Dermatophytosis
- Mucormycosis
- Others
|
- Superficial
Fungal Infection
- Systemic
Fungal Infection
|
- Parenteral
- Topical
- Oral
- Others
|
- Homecare
- Hospitals
- Clinics
- Others
|
- Retail
Pharmacy
- Hospital
Pharmacy
- Online
Pharmacy
|
|
Report Scope:
In this report, the India Anti-Fungal Drugs Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- India Anti-Fungal Drugs
Market, By
Drug Class:
o Azoles
o Echinocandins
o Polyenes
o Allylamines
o Others
- India Anti-Fungal Drugs
Market, By
Indication:
o Candidiasis
o Aspergillosis
o Dermatophytosis
o Mucormycosis
o Others
- India Anti-Fungal Drugs
Market, By
Infection Type:
o Superficial Fungal Infection
o Systemic Fungal Infection
- India Anti-Fungal Drugs
Market, By
Route of Administration:
o Parenteral
o Topical
o Oral
o Others
- India Anti-Fungal Drugs
Market, By End-User:
o Homecare
o Hospitals & Clinics
o Others
- India Anti-Fungal Drugs
Market, By Distribution Channel:
o Retail Pharmacy
o Hospital Pharmacy
o Online Pharmacy
- India Anti-Fungal Drugs Market, By Region:
o North
o
South
o
East
o
West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the India
Anti-Fungal Drugs Market.
Available Customizations:
India Anti-Fungal Drugs Market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
India Anti-Fungal Drugs Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]